Gene Review:
PDZD2 - PDZ domain containing 2
Homo sapiens
Synonyms:
AIPC, Activated in prostate cancer protein, KIAA0300, PAPIN, PDZ domain-containing protein 2, ...
Hernes,
Fosså,
Berner,
Otnes,
Nesland,
Beer,
Eilers,
Garzotto,
Egorin,
Lowe,
Henner,
Beer,
Garzotto,
Henner,
Eilers,
Wersinger,
Ameer,
Crumpler,
Langer,
Mathew,
Thall,
Jones,
Perez,
Bucana,
Troncoso,
Kim,
Fidler,
Logothetis,
Figg,
Liu,
Arlen,
Gulley,
Steinberg,
Liewehr,
Cox,
Zhai,
Cremers,
Parr,
Yang,
Chen,
Jones,
Dahut,
Scholz,
Jennrich,
Strum,
Brosman,
Johnson,
Lam,
- Secreted PDZD2 exerts concentration-dependent effects on the proliferation of INS-1E cells. Ma, R.Y., Tam, T.S., Suen, A.P., Yeung, P.M., Tsang, S.W., Chung, S.K., Thomas, M.K., Leung, P.S., Yao, K.M. Int. J. Biochem. Cell Biol. (2006)
- Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor. Tam, C.W., Cheng, A.S., Ma, R.Y., Yao, K.M., Shiu, S.Y. Endocrinology (2006)
- Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. Chaib, H., Rubin, M.A., Mucci, N.R., Li, L., Taylor JMG, n.u.l.l., Day, M.L., Rhim, J.S., Macoska, J.A. Cancer Res. (2001)
- Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Mathew, P., Thall, P.F., Jones, D., Perez, C., Bucana, C., Troncoso, P., Kim, S.J., Fidler, I.J., Logothetis, C. J. Clin. Oncol. (2004)
- PIN1 expression contributes to hepatic carcinogenesis. Pang, R.W., Lee, T.K., Man, K., Poon, R.T., Fan, S.T., Kwong, Y.L., Tse, E. J. Pathol. (2006)
- Structure and dynamics of pin1 during catalysis by NMR. Labeikovsky, W., Eisenmesser, E.Z., Bosco, D.A., Kern, D. J. Mol. Biol. (2007)
- Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. Scholz, M., Jennrich, R., Strum, S., Brosman, S., Johnson, H., Lam, R. J. Urol. (2005)
- Myc confers androgen-independent prostate cancer cell growth. Bernard, D., Pourtier-Manzanedo, A., Gil, J., Beach, D.H. J. Clin. Invest. (2003)
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Dahut, W.L., Gulley, J.L., Arlen, P.M., Liu, Y., Fedenko, K.M., Steinberg, S.M., Wright, J.J., Parnes, H., Chen, C.C., Jones, E., Parker, C.E., Linehan, W.M., Figg, W.D. J. Clin. Oncol. (2004)
- Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Beer, T.M., Eilers, K.M., Garzotto, M., Egorin, M.J., Lowe, B.A., Henner, W.D. J. Clin. Oncol. (2003)
- Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. Oh, W.K., Kantoff, P.W., Weinberg, V., Jones, G., Rini, B.I., Derynck, M.K., Bok, R., Smith, M.R., Bubley, G.J., Rosen, R.T., DiPaola, R.S., Small, E.J. J. Clin. Oncol. (2004)
- Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Hernes, E., Fosså, S.D., Berner, A., Otnes, B., Nesland, J.M. Br. J. Cancer (2004)
- Pin1 allows for differential Tau dephosphorylation in neuronal cells. Hamdane, M., Dourlen, P., Bretteville, A., Sambo, A.V., Ferreira, S., Ando, K., Kerdraon, O., Bégard, S., Geay, L., Lippens, G., Sergeant, N., Delacourte, A., Maurage, C.A., Galas, M.C., Buée, L. Mol. Cell. Neurosci. (2006)
- Functionally Important Residues in the Peptidyl-prolyl Isomerase Pin1 Revealed by Unigenic Evolution. Behrsin, C.D., Bailey, M.L., Bateman, K.S., Hamilton, K.S., Wahl, L.M., Brandl, C.J., Shilton, B.H., Litchfield, D.W. J. Mol. Biol. (2007)
- Pin1 in Alzheimer's disease. Butterfield, D.A., Abdul, H.M., Opii, W., Newman, S.F., Joshi, G., Ansari, M.A., Sultana, R. J. Neurochem. (2006)
- Proteolytic cleavage of PDZD2 generates a secreted peptide containing two PDZ domains. Yeung, M.L., Tam, T.S., Tsang, A.C., Yao, K.M. EMBO Rep. (2003)
- PAPIN. A novel multiple PSD-95/Dlg-A/ZO-1 protein interacting with neural plakophilin-related armadillo repeat protein/delta-catenin and p0071. Deguchi, M., Iizuka, T., Hata, Y., Nishimura, W., Hirao, K., Yao, I., Kawabe, H., Takai, Y. J. Biol. Chem. (2000)
- Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. Yu, L., Mohamed, A.J., Vargas, L., Berglöf, A., Finn, G., Lu, K.P., Smith, C.I. J. Biol. Chem. (2006)
- A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Imbriaco, M., Larson, S.M., Yeung, H.W., Mawlawi, O.R., Erdi, Y., Venkatraman, E.S., Scher, H.I. Clin. Cancer Res. (1998)
- Proteolytic nicking of the acetylcholine receptor. Lindstrom, J., Gullick, W., Conti-Tronconi, B., Ellisman, M. Biochemistry (1980)
- Cell-killing potential of a water-soluble radical initiator. Ameer, G.A., Crumpler, E.T., Langer, R. Int. J. Cancer (2001)
- Localization of p0071-interacting proteins, plakophilin-related armadillo-repeat protein-interacting protein (PAPIN) and ERBIN, in epithelial cells. Ohno, H., Hirabayashi, S., Iizuka, T., Ohnishi, H., Fujita, T., Hata, Y. Oncogene (2002)
- GABAB Receptor Association with the PDZ Scaffold Mupp1 Alters Receptor Stability and Function. Balasubramanian, S., Fam, S.R., Hall, R.A. J. Biol. Chem. (2007)
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Bubley, G.J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W.D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D.P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J., Sinibaldi, V., Small, E.J., Smith, M.R., Trump, D.L., Wilding, G. J. Clin. Oncol. (1999)
- Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Beer, T.M., Garzotto, M., Henner, W.D., Eilers, K.M., Wersinger, E.M. Br. J. Cancer (2004)
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. Figg, W.D., Liu, Y., Arlen, P., Gulley, J., Steinberg, S.M., Liewehr, D.J., Cox, M.C., Zhai, S., Cremers, S., Parr, A., Yang, X., Chen, C.C., Jones, E., Dahut, W.L. J. Urol. (2005)